Geriatric Psychiatry

Abstract

Geriatric psychiatry is a type of psychiatry concerned with the assessment, treatment, and prevention of mental disorders in older adults. It treats late life not as a period of inevitable decline but as a stage with a distinctive psychiatric profile, in which cognitive, mood, and medical processes interact and the same symptom can arise from strikingly different causes. Its clinical core is the differential diagnosis of the three overlapping syndromes that dominate old-age presentation — dementia, delirium, and depression — and the recognition that each is separable, and each treatable, when read correctly. As the world's population ages and the number of people living with dementia is projected to rise steeply, the field's questions about detection, mechanism, and prevention have moved to the center of global health.

Keywords: geriatric psychiatry, late-life depression, dementia, delirium, cognitive screening

Geriatric psychiatry, also called old-age or psychogeriatric psychiatry, exists because the psychiatry of later life is not simply general psychiatry applied to older patients. Disorders present atypically, cognitive and physical illness are woven together, medications behave differently in an aging body, and the base rates of the major syndromes shift dramatically. This article traces the field from its scope and origins, through the assessment problem that defines its daily work — telling dementia, delirium, and depression apart — to the two conditions that account for most of its burden: late-life depression and the dementias, the latter now framed as a partly preventable disorder of global scale (GBD 2019 Dementia Forecasting Collaborators, 2022).

Scope and Origins

Geriatric psychiatry emerged as a distinct discipline in the second half of the twentieth century, as lengthening life expectancy made the psychiatric care of older adults a large and specialized enterprise. Its remit is defined less by an age threshold than by a set of recurring problems: disorders that present atypically in later life, the dense entanglement of psychiatric and physical illness, the altered pharmacokinetics of an aging body, and a syndrome mix dominated by cognitive disorders and mood disorders rather than the conditions that define younger-adult psychiatry. The field's founding insight is that these features interact, so that a competent geriatric assessment must read mind, brain, and body together.

The scale of the field is set largely by dementia. A Global Burden of Disease analysis estimated that about 57.4 million people were living with dementia worldwide in 2019 and projected that number to reach roughly 152.8 million by 2050, an increase driven chiefly by population aging and growth (GBD 2019 Dementia Forecasting Collaborators, 2022). That trajectory, shown in Figure 1, is what has moved geriatric psychiatry from a niche specialty to a discipline at the center of global health planning, and it is why the field's attention has turned increasingly toward prevention and early detection rather than late-stage management alone.

Assessment: The Three D's and Cognitive Screening

The defining diagnostic problem of geriatric psychiatry is that its three most common syndromes — dementia, delirium, and depression, the three D's — share surface features while differing profoundly in cause, course, and treatment. All three can present with poor memory, slowed thinking, and functional decline, yet dementia is an insidious and usually progressive loss of cognition, delirium an acute and fluctuating disturbance of attention and awareness, and depression a mood disorder that can mimic cognitive decline. Distinguishing them is not academic: delirium signals acute medical illness and is often reversible, depression is treatable, and mislabeling either as irreversible dementia forecloses effective care.

Delirium is the most urgent of the three because it marks an underlying medical emergency and because its cardinal feature is a disturbance of attention with an acute onset and a fluctuating course (Inouye, 2006). The Confusion Assessment Method operationalizes exactly this profile, requiring acute onset with fluctuation and inattention plus either disorganized thinking or an altered level of consciousness, and it remains the standard bedside instrument for detecting delirium. Depression presenting as apparent cognitive impairment — historically termed pseudodementia — is separated from dementia by its subacute onset, its mood-congruent complaints, and its reversibility with treatment.

Cognitive screening supports this differential, and the choice of instrument matters. The Mini-Mental State Examination, introduced as a practical bedside method for grading cognitive state, became the most widely used screen for established dementia (Folstein et al., 1975). It is comparatively insensitive, however, to the milder deficits of mild cognitive impairment. The Montreal Cognitive Assessment was designed to close that gap, sampling executive function, attention, and delayed recall more demandingly; in its validation study it detected the great majority of mild cognitive impairment cases that the MMSE missed, at the cost of somewhat lower specificity (Nasreddine et al., 2005). The three D's are summarized feature by feature in Table 1, and the interactive tools below make the same contrasts manipulable and show how the two screens diverge on mild impairment.

Telling the three D’s apart

Build a clinical profile. The demo scores each syndrome by how closely its canonical picture matches your choices, and names the best fit.

Best fit: Delirium (3 of 3 features match its canonical picture).

Which screen catches mild impairment?

Detection rate (sensitivity) of the two brief screens at a cutoff below 26. Switch the target group to see how the gap between them changes.

In mild cognitive impairment, the MoCA detects 72 points more than the MMSE (90% versus 18%).

Late-Life Depression

Depression in older adults is common, disabling, and frequently missed, in part because it presents with somatic and cognitive complaints more than with expressed sadness (Blazer, 2003). Its epidemiology in late life differs from that in younger adults: fewer classic melancholic presentations, more medical comorbidity, and a strong association with vascular disease (Alexopoulos, 2005). A distinctive and clinically important variant is the depression that arises in the context of cerebrovascular disease.

The vascular depression hypothesis proposes that cerebrovascular disease can predispose to, precipitate, or perpetuate a late-life depressive syndrome, giving rise to a clinical picture marked by executive dysfunction, psychomotor slowing, and relative resistance to standard antidepressants (Alexopoulos et al., 1997). This account reframed a subset of late-life depression as a disorder of brain circuitry rather than a purely psychological reaction to aging, and later work extended it into a network model in which disrupted frontostriatal and frontolimbic connectivity underlies both the mood and the executive features (Alexopoulos, 2019). A broader review of mechanism and treatment situates vascular contributions alongside neurodegenerative and inflammatory ones (Taylor, 2014).

Treatment evidence in late-life depression is developmentally specific in its own way, and its most consequential lesson concerns maintenance. In a controlled trial of patients aged seventy and older who had recovered from major depression, continuation treatment substantially reduced the rate of recurrence relative to placebo, establishing that keeping older patients well requires ongoing rather than merely acute treatment (Reynolds et al., 2006). A later synthesis of management options confirmed that antidepressants and structured psychotherapies are both effective and that combined and maintenance strategies carry the strongest evidence for preventing relapse (Kok & Reynolds, 2017). The stakes are high because late-life depression is a leading risk factor for suicide, and rates of suicide are elevated in older adults, particularly older men (Conwell et al., 2011). Where depression coexists with dementia, the mood disorder must be rated with an instrument designed for that setting, such as the Cornell Scale for Depression in Dementia, which draws on caregiver as well as patient information (Alexopoulos et al., 1988).

Dementia and Its Modifiable Risk

Dementia is a syndrome of acquired, progressive cognitive decline severe enough to impair everyday function, reclassified in current nosology as major neurocognitive disorder to emphasize its graded relationship to the milder mild neurocognitive disorder (Sachdev et al., 2014). Its course has long been described in stages; the Global Deterioration Scale provided an early and durable seven-stage framework for charting the progression from normal aging through mild cognitive impairment to severe dementia (Reisberg et al., 1982). Cognitive loss, however, is only part of the clinical picture.

The neuropsychiatric symptoms of dementia — agitation, apathy, depression, delusions, hallucinations, disturbances of sleep and appetite, and the late-day worsening of confusion known as sundowning — are nearly universal over the course of the illness and are often more distressing to patients and caregivers than the memory loss itself. A population study found that these symptoms were highly prevalent even in mild cognitive impairment and reached the great majority of patients with dementia (Lyketsos et al., 2002). Their systematic measurement was made feasible by the Neuropsychiatric Inventory, which assesses the range of behavioral disturbances in a single caregiver-based instrument and became the standard tool for the purpose (Cummings et al., 1994).

What has most changed the field's outlook is evidence that dementia is partly preventable. The Lancet Commission on dementia prevention, intervention, and care synthesized the epidemiology into a life-course model of modifiable risk factors, concluding that around 40% of dementias worldwide are theoretically attributable to twelve such factors and could in principle be prevented or delayed by addressing them (Livingston et al., 2020). The factors span the life course — less education in early life; hearing loss, traumatic brain injury, hypertension, harmful alcohol use, and obesity in midlife; and smoking, depression, social isolation, physical inactivity, air pollution, and diabetes in later life. The demonstration below allows these factors to be added and removed, accumulating their combined population attributable fraction.

How much dementia risk is modifiable?

Each chip is a modifiable risk factor with its overlap-adjusted attributable fraction. Toggle factors to accumulate the preventable share; all twelve together reach 40%.

Modifiable risk selected: 40% of dementia

Worked Example

Consider how the Lancet Commission arrives at its headline figure, using the population attributable fraction — the share of cases that would not occur if a risk factor were removed. The Commission assigns each of its twelve modifiable factors a weighted attributable fraction, adjusted so that the overlap between correlated factors is not double-counted (Livingston et al., 2020).

Grouped by life stage, the weighted fractions are: in early life, less education at 7%; in midlife, hearing loss at 8%, traumatic brain injury at 3%, hypertension at 2%, harmful alcohol use at 1%, and obesity at 1%; and in later life, smoking at 5%, depression at 4%, social isolation at 4%, physical inactivity at 2%, air pollution at 2%, and diabetes at 1%. Summing the early-life contribution of 7 percentage points, the midlife total of 8 + 3 + 2 + 1 + 1 = 15 percentage points, and the later-life total of 5 + 4 + 4 + 2 + 2 + 1 = 18 percentage points gives 7 + 15 + 18 = 40 percentage points. That is the origin of the claim that roughly 40% of dementia is attributable to modifiable risk: not a single dominant cause, but a dozen moderate ones that, because they are weighted to avoid double-counting, sum to a large and actionable total. The clinical reading is that prevention is diffuse work spread across the life course rather than a single intervention late in it.

Discussion

Geriatric psychiatry is organized around a small number of mutually reinforcing facts: that late-life disorders present atypically, that its three signature syndromes overlap yet demand different responses, and that its heaviest burden — dementia — is both rising steeply and partly preventable. The differential of the three D's is the field's daily discipline, and it is unforgiving in both directions, because calling reversible delirium or treatable depression an irreversible dementia abandons a patient who could recover, while missing a true dementia delays support that families need. The shift from viewing dementia as a fixed endpoint to viewing it as a partly modifiable outcome is the field's most consequential reframing, aligning geriatric psychiatry with public health rather than palliation alone.

The same developmental logic that governs assessment governs treatment. Late-life depression is not adult depression grown old; it carries a vascular signature, a distinctive executive profile, and a maintenance requirement that acute-treatment models miss. Managing it well means treating to remission and then keeping patients well, precisely because recurrence and its downstream risk of suicide are the field's gravest outcomes. Across cognition and mood alike, the recurring theme is that older patients reward careful, longitudinal reading and are harmed by the assumption that decline is simply age.

Current Directions

The most active contemporary work extends the prevention agenda and sharpens the mechanistic account of mood disorder. Building on the Lancet Commission framework, research now asks not only which risk factors matter but how much of the population-level benefit can actually be realized through feasible interventions, and how modifiable risk interacts with genetic vulnerability across the life course (Livingston et al., 2020). The prevention model has reframed midlife hearing loss, hypertension, and physical inactivity as targets for dementia risk reduction, moving the intervention window decades earlier than treatment traditionally reached.

In late-life depression, the network account of frontostriatal and frontolimbic dysfunction is guiding a search for mechanism-matched treatments, including approaches aimed at the executive dysfunction that predicts poor antidepressant response rather than at mood symptoms alone (Alexopoulos, 2019). Alongside this, syntheses of the treatment evidence continue to refine how antidepressants, psychotherapies, and their combination should be sequenced and maintained in older adults with medical comorbidity (Kok & Reynolds, 2017). The common thread is a move from managing established illness toward intervening earlier and more precisely, on mechanisms rather than surface symptoms.

Common Misconceptions

Memory loss and confusion in an older person mean dementia.

An acute, fluctuating disturbance of attention is far more likely to be delirium, which signals medical illness and is often reversible; treating it as dementia misses a treatable emergency (Inouye, 2006).

Depression is a normal, understandable part of growing old.

Late-life depression is a disorder, not an expected feature of aging; it is treatable and, left untreated, is a leading contributor to suicide in older adults (Conwell et al., 2011).

Dementia is entirely genetic and cannot be prevented.

Around 40% of dementia risk is attributable to modifiable factors across the life course, so a substantial share is in principle preventable or delayable (Livingston et al., 2020).

Glossary

Confusion Assessment Method.

A structured bedside algorithm for detecting delirium, requiring acute onset with fluctuation and inattention plus disorganized thinking or an altered level of consciousness.

Cornell Scale for Depression in Dementia.

An instrument for rating depression in people with dementia that combines clinician observation with caregiver report, accommodating patients who cannot reliably self-report.

Delirium.

An acute, fluctuating disturbance of attention and awareness caused by an underlying medical condition, often reversible and a medical emergency in older adults.

Dementia.

A syndrome of acquired, progressive cognitive decline severe enough to impair independent daily function, reclassified as major neurocognitive disorder in current nosology.

Global Deterioration Scale.

A seven-stage framework charting the progression of primary degenerative dementia from normal cognition through mild cognitive impairment to severe decline.

Late-life depression.

Depression arising in older adults, distinguished by more somatic and cognitive complaints, greater medical comorbidity, and a strong association with vascular disease.

Major neurocognitive disorder.

The current diagnostic term for dementia, defined by significant cognitive decline that interferes with independence, graded against milder neurocognitive impairment.

Mild cognitive impairment.

A measurable decline in cognition that does not yet impair everyday function, often a transitional stage between normal aging and dementia.

Mini-Mental State Examination.

A widely used brief cognitive screen scored out of thirty points, sensitive to established dementia but relatively insensitive to mild cognitive impairment.

Montreal Cognitive Assessment.

A brief screen designed to detect mild cognitive impairment, sampling executive function, attention, and delayed recall more demandingly than the MMSE.

Neuropsychiatric symptoms.

The behavioral and psychological disturbances of dementia, including agitation, apathy, depression, delusions, and hallucinations, often more distressing than cognitive loss.

Population attributable fraction.

The proportion of disease cases in a population that would not occur if a given risk factor were eliminated, used to weigh modifiable dementia risk.

Pseudodementia.

Apparent cognitive impairment produced by depression rather than a neurodegenerative process, separable from dementia by its subacute onset and reversibility.

Sundowning.

A worsening of confusion and agitation in the late afternoon and evening seen in some people with dementia and delirium.

Vascular depression.

A hypothesized late-life depressive syndrome in which cerebrovascular disease predisposes to or perpetuates depression, marked by executive dysfunction and treatment resistance.

Key Researchers

George S. Alexopoulos (living). Director of the Weill Cornell Institute of Geriatric Psychiatry; he proposed the vascular depression hypothesis and co-developed the Cornell Scale for Depression in Dementia. ORCID

Dan G. Blazer (b. 1944). Psychiatric epidemiologist at Duke University whose studies defined the prevalence, presentation, and course of depression in later life. Wikipedia

Sharon K. Inouye (living). Geriatrician at the Marcus Institute for Aging Research and Harvard Medical School; she developed the Confusion Assessment Method, the standard bedside instrument for detecting delirium. Wikipedia

Gill Livingston (living). Professor of psychiatry of older people at University College London; she chairs the Lancet Commission that quantified the modifiable risk factors for dementia. ORCID · Wikipedia

Constantine G. Lyketsos (b. 1961). Professor of psychiatry at Johns Hopkins University; his Cache County and Cardiovascular Health Study work established the prevalence and course of neuropsychiatric symptoms in dementia. ORCID · Wikipedia

Ziad Nasreddine (living). Neurologist who created the Montreal Cognitive Assessment, the most widely used brief screen for mild cognitive impairment. ORCID · Wikipedia

Charles F. Reynolds (living). Professor of geriatric psychiatry at the University of Pittsburgh; his maintenance-treatment trials established how to prevent recurrence of major depression in old age. ORCID · Wikipedia

Frequently Asked Questions

What is geriatric psychiatry? It is the branch of psychiatry concerned with the assessment, treatment, and prevention of mental disorders in older adults, treating late life as a stage with its own psychiatric profile (Blazer, 2003).

What are the three D's of geriatric psychiatry? They are dementia, delirium, and depression, the three overlapping syndromes that dominate old-age presentation and that must be told apart because each has a different course and treatment (Inouye, 2006).

How is delirium distinguished from dementia? Delirium has an acute onset and a fluctuating course with prominent inattention and often signals a reversible medical illness, whereas dementia is insidious and progressive; the Confusion Assessment Method captures the delirium profile (Inouye, 2006).

Why use the MoCA instead of the MMSE? The Montreal Cognitive Assessment was designed to detect mild cognitive impairment, and in its validation it identified the great majority of such cases that the less demanding MMSE missed (Nasreddine et al., 2005).

What is vascular depression? It is a proposed late-life depressive syndrome in which cerebrovascular disease predisposes to or perpetuates depression, producing prominent executive dysfunction and relative resistance to standard antidepressants (Alexopoulos et al., 1997).

Can late-life depression be treated effectively? Yes; antidepressants and structured psychotherapies both work, and maintenance treatment after recovery substantially reduces the risk of recurrence in older patients (Reynolds et al., 2006).

How much dementia is preventable? A life-course analysis concluded that about 40% of dementia is attributable to twelve modifiable risk factors and could in principle be prevented or delayed by addressing them (Livingston et al., 2020).

Are behavioral symptoms common in dementia? Yes; neuropsychiatric symptoms such as agitation, apathy, and depression affect the great majority of people with dementia over the illness and are often more distressing than memory loss itself (Lyketsos et al., 2002).

References